Nevis Brands, Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. It focuses on the following technologies: PAS-403 for glioblastoma, PAS-393 for cancer, and Pre-BCR Antibody for leukemia. The company was founded by Wilfred Jefferies on January 28, 2011 and is headquartered in Vancouver, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company